Recent Investment Analysts’ Ratings Updates for Edwards Lifesciences (EW)

A number of research firms have changed their ratings and price targets for Edwards Lifesciences (NYSE: EW):

• 7/28/2026 – Edwards Lifesciences is now covered by UBS Group AG. They set a “buy” rating and a $110.00 price target on the stock.
• 7/24/2026 – Edwards Lifesciences had its “overweight” rating reaffirmed by Piper Sandler. They now have a $101.00 price target on the stock, up from $100.00.
• 7/24/2026 – Edwards Lifesciences had its price target raised by JPMorgan Chase & Co. from $100.00 to $105.00. They now have an “overweight” rating on the stock.
• 7/24/2026 – Edwards Lifesciences was upgraded by Leerink Partners from “market perform” to “outperform”. They now have a $101.00 price target on the stock, up from $87.00.
• 7/21/2026 – Edwards Lifesciences had its “buy” rating reaffirmed by TD Cowen.
• 7/17/2026 – Edwards Lifesciences had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 7/16/2026 – Edwards Lifesciences had its price target raised by Truist Financial Corporation from $90.00 to $95.00. They now have a “hold” rating on the stock.
• 7/15/2026 – Edwards Lifesciences had its price target raised by Mizuho from $100.00 to $105.00. They now have an “outperform” rating on the stock.
• 7/13/2026 – Edwards Lifesciences had its price target raised by Royal Bank Of Canada from $100.00 to $110.00. They now have an “outperform” rating on the stock.
• 7/8/2026 – Edwards Lifesciences had its price target raised by Citigroup Inc. from $101.00 to $110.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Edwards Lifesciences had its “outperform” rating reaffirmed by Evercore Inc. They now have a $100.00 price target on the stock.
• 7/4/2026 – Edwards Lifesciences was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/30/2026 – Edwards Lifesciences had its price target raised by BTIG Research from $100.00 to $110.00. They now have a “buy” rating on the stock.
• 6/16/2026 – Edwards Lifesciences had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $100.00 price target on the stock.
• 6/2/2026 – Edwards Lifesciences had its “buy” rating reaffirmed by TD Cowen. They now have a $104.00 price target on the stock, up from $97.00.

Insiders Place Their Bets

In related news, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the sale, the vice president owned 98,611 shares of the company’s stock, valued at $8,521,962.62. This trade represents a 19.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $83.01, for a total transaction of $84,587.19. Following the completion of the transaction, the vice president owned 33,934 shares of the company’s stock, valued at approximately $2,816,861.34. The trade was a 2.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 45,577 shares of company stock valued at $3,855,527. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.